Clinical trial
Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
NCT00003914 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00003914 |
|---|---|
| Title | Dolastatin 10 in Treating Patients With Advanced Kidney Cancer |
| Official title | Phase II Study of Dolastatin-10 in Patients With Advanced Renal Cell Carcinoma |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | dolastatin 10 |
| Enrollment | 30 |
| Start date | Aug 1, 1999 |
| Primary completion | Aug 1, 2002 |
| Completion | May 1, 2009 |
| First posted | Apr 27, 2004 |
| Last update posted | May 11, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: